ヘモグロビン異常症市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、診断別、療法別、地域別、競合別、2019年～2029年

ヘモグロビン異常症の世界市場は、2023年に83億米ドルと評価され、2029年までのCAGRは12.59%で、予測期間中に力強い成長が予測されています。

世界のヘモグロビン異常症市場は、異常ヘモグロビンに関連する疾患を取り巻く経済状況を指し、鎌状赤血球症とサラセミアに主な焦点が置かれています。これらの疾患は、赤血球中で酸素を運搬する役割を担うタンパク質であるヘモグロビンの構造異常を特徴とする遺伝性血液疾患です。

ヘモグロビン異常症の世界市場は、これらの疾患の世界の有病率の高さを反映して、かなりの規模となっています。世界のヘモグロビン異常症市場は、疾患の診断とスクリーニングの分野における技術の進歩によって牽引されています。政府・非政府組織、患者支援団体、製薬バイオテクノロジー企業によるヘモグロビン異常症に関する意識向上への努力は、疾患の早期診断、より良い疾患管理、治療選択肢に対する需要の増加に寄与しています。このことは、2029年までの世界のヘモグロビン異常症市場の成長に有利な機会を生み出すと期待されています。さらに、ヘモグロビン異常症の治療のための遺伝子治療などの新規治療法の開発のための研究開発への注目の高まりは、今後数年間の世界のヘモグロビン異常症市場の成長をサポートすると予想されます。

主な市場促進要因

診断技術の進歩

新規治療法の承認

新生児スクリーニングプログラム

世界の疾患負担と認知度の向上

主な市場課題

ヘルスケアサービスへのアクセス制限

高額な治療費

遺伝的・倫理的配慮

主な市場動向

治療アプローチの進歩

精密医療と個別化医療

セグメント別洞察

タイプ別洞察

診断別洞察

療法別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別（サラセミア、鎌状赤血球症、その他のヘモグロビン（Hb）変異体）
  • 診断別（サラセミア｛血液検査、遺伝子検査、出生前遺伝子検査、着床前遺伝子診断、電気泳動、その他｝、鎌状赤血球症｛血液検査、遺伝子検査、出生前遺伝子検査、電気泳動、その他｝、その他｛血液検査、遺伝子検査、出生前遺伝子検査、電気泳動、その他｝）
  • 療法別（サラセミア｛輸血、鉄キレート療法、骨髄移植、その他｝、鎌状赤血球症｛輸血、ヒドロキシ尿素、骨髄移植、その他｝、その他｛輸血、ヒドロキシ尿素、鉄キレート療法、骨髄移植、その他｝）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米のヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 診断別
  • 療法別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 診断別
  • 療法別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 診断別
  • 療法別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 診断別
  • 療法別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのヘモグロビン異常症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 診断別
  • 療法別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品発表
• 合併・買収

第13章 ヘモグロビン異常症の世界市場SWOT分析

第14章 競合情勢

• Sangamo Therapeutics, Inc.
• Pfizer, Inc.（Global Blood Therapeutics, Inc.）
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi S.A.（Bioverativ Inc.）
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

第15章 戦略的提言

第16章 免責事項

Global Hemoglobinopathies Market was valued at USD 8.30 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 12.59% through 2029. The Global Hemoglobinopathies Market refers to the economic landscape surrounding diseases related to abnormal hemoglobin, with a primary focus on sickle cell disease and thalassemia. These conditions are genetic blood disorders characterized by structural abnormalities in hemoglobin, the protein responsible for carrying oxygen in red blood cells.

Global Hemoglobinopathies Market is substantial, reflecting the high prevalence of these conditions worldwide. The global hemoglobinopathies market is driven by technological advancements in the field of disease diagnosis and screening. The efforts made by government and non-government organizations, patient advocacy groups and pharmaceutical biotechnology companies to raise awareness about hemoglobinopathies are contributing to early disease diagnosis, better disease management and increased demand for treatment options. This in turn is expected to create lucrative opportunities for the growth of global hemoglobinopathies market through 2029. Additionally, the growing focus on research and development for development of novel therapies such as gene therapies for the treatment of hemoglobinopathies is expected to support the growth of global hemoglobinopathies market in the coming years.

Key Market Drivers

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies have played a pivotal role in driving the growth of the Global Hemoglobinopathies Market. These advancements have significantly improved the accuracy, efficiency, and accessibility of diagnosing hemoglobinopathies, such as sickle cell disease and thalassemia. The key components of these advancements is the breakthrough in genetic testing techniques. Next-generation sequencing (NGS) and molecular diagnostics have revolutionized the way hemoglobinopathies are diagnosed. NGS, in particular, allows for comprehensive analysis of a patient's genetic makeup, enabling the identification of specific mutations and variations associated with hemoglobinopathies. This level of precision in diagnosis not only improves patient outcomes but also aids in better-targeted treatment strategies.

The enhanced accuracy of genetic testing methods has a direct impact on early disease detection. Hemoglobinopathies can present a wide range of clinical manifestations, and early diagnosis is crucial for effective disease management. The ability to identify these conditions at a genetic level allows for earlier intervention and more timely treatment, which can prevent complications and improve the quality of life for patients. Another important aspect of diagnostic technology advancement is the development of point-of-care testing (POCT) devices and rapid diagnostic kits. These innovations have made it possible to conduct diagnostic tests at the patient's bedside, in clinics, or even in remote and underserved areas. This accessibility is particularly important in regions with a high prevalence of hemoglobinopathies, where healthcare infrastructure may be limited. Rapid diagnostic kits provide quick results, enabling healthcare professionals to make timely decisions regarding patient care.

Advancements in diagnostic technologies often involve collaborations between biotechnology companies, medical device manufacturers, and research institutions. For example, in May 2023, Molbio Diagnostics collaborated with ShanMukha Innovations to design, develop, and commercialize point-of-care diagnostic devices for hemoglobinopathy-related diseases. Such partnerships facilitate the translation of research into market-ready products, increasing the availability of cutting-edge diagnostic tools. As diagnostic technologies continue to evolve, the hemoglobinopathies market has witnessed substantial growth. The introduction of new diagnostic tools has expanded the market's offerings and has led to increased competition among companies to develop more efficient and cost-effective solutions. This competition has driven further innovation, benefiting patients and healthcare providers alike.

Approval Of Novel Therapies

The approval of novel therapies has been a significant market driver for the growth of the Global Hemoglobinopathies Market. These novel therapies, including gene therapies and targeted therapies, have the potential to transform the treatment landscape for hemoglobinopathies, such as sickle cell disease and thalassemia. The most notable breakthroughs in the treatment of hemoglobinopathies has been in the field of gene therapies. These therapies aim to modify the underlying genetic abnormalities responsible for these conditions. For instance, gene therapy for sickle cell disease involves modifying the patient's own hematopoietic stem cells to produce normal hemoglobin. These treatments have shown promise in clinical trials, offering the potential for long-term disease modification or even a cure. The approval and commercialization of gene therapies represent a paradigm shift in the management of hemoglobinopathies.

Alongside gene therapies, targeted therapies have also gained approvals and are making a significant impact. These therapies are designed to manage the symptoms and complications associated with hemoglobinopathies. For example, hydroxyurea, a medication that increases fetal hemoglobin levels, has been approved for use in sickle cell disease. It helps reduce pain crises and improve the overall quality of life for patients. The approval of such targeted therapies has provided patients with more effective and tailored treatment options. The approval of gene therapies, in particular, offers the potential for a cure. Patients with hemoglobinopathies, who may have previously relied on palliative care and symptom management, now have access to treatments that can modify their genetic abnormalities and potentially eliminate the need for lifelong treatments. This curative potential has generated significant interest and excitement among patients, healthcare providers, and the pharmaceutical industry.

The emergence and approval of novel therapies have expanded the Hemoglobinopathies Market. Pharmaceutical companies and biotech firms are investing heavily in research and development to bring these therapies to market. This has led to increased competition and innovation, resulting in a broader range of treatment options for patients.As these therapies gain approval, there is a growing focus on ensuring broad patient access. Efforts are being made to make these novel treatments available to a wider population, including underserved and marginalized communities. Patient access programs, reimbursement support, and partnerships with healthcare institutions aim to overcome potential barriers to accessing these innovative therapies.

Newborn Screening Programs

Newborn screening programs have emerged as a significant market driver for the growth of the Global Hemoglobinopathies Market. These programs, which focus on early detection and intervention in infants, play a vital role in improving patient outcomes and expanding the market. Newborn screening programs are designed to identify hemoglobinopathies, such as sickle cell disease and thalassemia, in infants shortly after birth. Early detection is crucial for timely intervention, as it enables healthcare providers to initiate appropriate treatments and management strategies at the earliest possible stage. This can prevent complications, reduce the severity of the disease, and ultimately improve the quality of life for affected infants.

Newborn screening not only aids in early diagnosis but also facilitates the implementation of preventative measures. For instance, infants identified through screening can be started on prophylactic antibiotics to reduce the risk of serious infections. This proactive approach significantly reduces morbidity and mortality associated with hemoglobinopathies, contributing to better health outcomes and reduced healthcare costs in the long run. Hemoglobinopathies are not limited to specific geographic regions, they affect populations worldwide. In many countries, the prevalence of these conditions is significant. For example, in some African countries, a substantial percentage of the population carries the sickle cell gene, leading to a higher disease prevalence. This global impact has driven the implementation of newborn screening programs in various parts of the world, creating a broad market for screening technologies and services.

As awareness of the benefits of newborn screening has increased, so has the adoption of these programs by healthcare systems and governments. The growing acceptance of the importance of early disease detection and intervention has driven market growth. Healthcare authorities are recognizing the long-term cost savings and health improvements associated with newborn screening. Advances in diagnostic technologies have enhanced the accuracy and efficiency of newborn screening for hemoglobinopathies. These technologies, such as high-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS), enable quick and reliable analysis of newborn blood samples. This ensures that infants with hemoglobinopathies are identified accurately, minimizing the risk of false positives or negatives.

Increasing Global Disease Burden and Awareness

The increasing global disease burden and awareness have been significant market drivers for the growth of the Global Hemoglobinopathies Market. The growing prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, and heightened awareness about these conditions have led to various factors contributing to market growth. Hemoglobinopathies, particularly sickle cell disease, have a considerable global disease burden. It is estimated that around 300,000 newborns are affected by these conditions annually. In many African countries, an estimated 10% to 40% of the population carries the sickle cell gene, leading to a prevalence of around 2% in these regions. The high incidence and prevalence of these conditions have made hemoglobinopathies a critical public health concern, which, in turn, has contributed to market growth.

Hemoglobinopathies are not limited to specific geographic regions; they affect populations worldwide. The conditions are prevalent in North America, South America, Asia, and Europe, in addition to Africa. As a result, the market for diagnostics, treatments, and support services for hemoglobinopathies has a global reach, driving growth across continents. The increasing disease burden has prompted healthcare systems and governments to allocate more resources to addressing hemoglobinopathies. This includes funding for research, diagnosis, treatment, and patient support services. The allocation of resources has led to market growth as pharmaceutical companies, diagnostic laboratories, and healthcare providers respond to the growing demand for innovative solutions.

The rise in awareness about hemoglobinopathies has been a pivotal driver for market growth. Advocacy groups, healthcare organizations, and governments have launched campaigns to educate the public, healthcare professionals, and policymakers about these conditions. The awareness efforts have focused on early diagnosis, prevention, and improving patient care, thereby driving the demand for diagnostics and treatments. Alongside diagnostic and treatment solutions, there is a growing emphasis on supportive care programs to improve the quality of life for individuals with hemoglobinopathies. These programs include pain management, infection prevention, nutritional support, and psychosocial services. Awareness about the importance of these supportive care interventions has contributed to market growth, as healthcare providers seek to enhance patient care.

Key Market Challenges

Limited Access to Healthcare Services

In many parts of the world, particularly in low- and middle-income countries, access to healthcare services remains limited. This can hinder the early diagnosis, treatment, and management of hemoglobinopathies. Diagnostic tests, therapies, and support services may not be readily available or affordable, leading to delayed or inadequate care for affected individuals.

Disparities in healthcare access and quality can disproportionately affect certain populations, including marginalized communities and underserved regions. These disparities can result in delayed diagnosis and suboptimal care for individuals with hemoglobinopathies, undermining efforts to improve patient outcomes and reduce the disease burden. The effectiveness of newborn screening programs and treatment options is closely tied to the existing healthcare infrastructure. Inadequate infrastructure, including shortages of healthcare professionals and diagnostic facilities, can slow down efforts to implement early diagnosis and appropriate care.

High Treatment Costs

Some of the novel and effective treatments for hemoglobinopathies, such as gene therapies and targeted therapies, can be costly. These high treatment expenses can be a major barrier to access for individuals without adequate health insurance coverage or in regions with limited financial resources.

The long-term management of hemoglobinopathies can place a considerable economic burden on both individuals and healthcare systems. Costs associated with regular monitoring, supportive care, and emergency interventions can be substantial, affecting the affordability of comprehensive care for patients. Ensuring that patients have access to affordable treatments and services is challenging in many healthcare systems. Negotiating favorable reimbursement and pricing agreements with healthcare payers and providers can be a complex process that impacts the affordability of treatments.

Genetic and Ethical Considerations

Hemoglobinopathies, particularly sickle cell disease, exhibit significant genetic diversity. The effectiveness of genetic therapies and treatments can vary based on an individual's specific genetic makeup. Tailoring treatments to individual patients can be complex and may require extensive genetic testing.

Genetic therapies raise important ethical questions, particularly in gene editing and stem cell transplantation. Issues related to informed consent, the potential for unintended genetic changes, and the long-term consequences of genetic modifications must be carefully considered and addressed.

Ethical considerations also extend to patients and communities affected by hemoglobinopathies. Cultural, religious, and personal beliefs can influence decisions about treatment options and genetic interventions. Respecting the autonomy and perspectives of affected individuals is a critical aspect of care.

Key Market Trends

Advancements in Therapeutic Approaches

One of the most significant trends in the hemoglobinopathies market is the rapid development and adoption of gene therapies. Gene therapies hold immense promise in treating conditions like sickle cell disease and thalassemia by modifying or replacing the defective genes responsible for these disorders. Several gene therapies have reached advanced stages of clinical trials, and some have already received regulatory approvals. For instance, in December 2023, US-FDA approved two groundbreaking treatments Casgevy and Lyfgenia, making the debut of cell-based gene therapiees for sickle cell disease in patients aged 12 and above. Casgevy stands out as the first FDA approved therapy employing a pioneering geome editing technology, CARISPR/Cas9, signifying a significant leap forward in gene therapy. Cagevy, is endorsed for managing sickle cell disease in patients aged 12 and older who experience recurring vaso-occlusive crises. While Lyfgenia utilizes a lentiviral vector for genetic alteration and is sanctioned for patients aged 12 and above with sickle cell disease and a background of vaso-occlusive events. Lyfgenia modifies the patient's blood stem cells to generate HbAT87Q, a gene therapy-derived hemoglobin functioning similarly to hemoglobin A, the typical adult hemoglobin in individuals unaffected by sickle cell disease.

Another notable trend is the emergence of targeted therapies designed to manage the symptoms and complications of hemoglobinopathies. These therapies are increasingly being adopted as they help reduce pain crises, improve quality of life, and decrease the frequency of severe complications. The continued development and approval of targeted therapies provide additional treatment options for patients. Stem cell transplantation, particularly from matched unrelated donors, is gaining traction as a curative treatment option for hemoglobinopathies. The refinement of transplantation techniques, increased donor registries, and the expansion of transplant programs have made this approach more accessible and effective.

Precision Medicine and Personalized Care

The adoption of precision medicine approaches is becoming a key trend in the hemoglobinopathies market. Advances in genetic and molecular profiling enable healthcare providers to understand the specific genetic mutations and variations in individual patients. This knowledge is instrumental in tailoring treatment strategies, including gene therapies, to the unique genetic characteristics of each patient.

A shift toward patient-centric care models is evident in the hemoglobinopathies market. These models prioritize individualized care, focusing on the physical, emotional, and social needs of patients. Healthcare providers work closely with patients to develop treatment plans that align with their preferences and goals, promoting a higher quality of life and better treatment adherence. The trend of personalized care extends to supportive care interventions. Pain management, nutritional support, psychosocial services, and educational resources are increasingly customized to address the specific needs of each patient, improving their overall experience and well-being.

Segmental Insights

Type Insights

Based on the category of Type, the Sickle Cell Disease segment dominated the global market for Hemoglobinopathies in 2023, owing to an increase in the prevalence of disease worldwide. The market's growth can also be attributed to the increased efforts of biopharmaceutical companies and nonprofit organizations dedicated to enhancing access to sickle cell disease (SCD) treatment.

Moreover, the market's expansion is influenced by awareness programs focused on disease diagnosis. For example, in the United States, various SCD awareness initiatives concentrate on promoting early diagnosis and providing support. Organizations like the Sickle Cell Disease Association of America (SCDAA) and their local chapters organize educational events, community workshops, and health fairs. They collaborate with healthcare professionals to offer free or subsidized screenings, genetic counseling, and educational resources to boost awareness and enhance early detection of SCD, particularly among high-risk populations. These factors are expected to drive the growth of this segment.

Diagnosis Insight

Based on the category of Diagnosis, the Sickle Cell Disease diagnosis segment dominated the global market for Hemoglobinopathies in 2023. The sickle cell disease diagnosis market has recently experienced significant trends. One notable trend is the advancement and uptake of innovative diagnostic technologies. Breakthroughs in genetic testing, such as next-generation sequencing and molecular diagnostics, have enabled more precise and efficient identification of sickle cell disease and its variations. In addition, there has been the emergence of point-of-care testing (POCT) devices and rapid diagnostic kits, allowing for swift and convenient screening in diverse healthcare settings.The hemoglobinopathies market has also seen a heightened focus on newborn screening programs, ensuring early detection and timely interventions. Furthermore, there is an increasing emphasis on expanding access to diagnostic services in underserved regions, thus enhancing overall patient care and outcomes.

Therapy Insights

The Sickle Cell Disease therapy segment is projected to experience rapid growth during the forecast period. The development and approval of innovative therapies, including gene and targeted therapies, with a focus on modifying genetic irregularities or managing disease symptoms, are significant drivers of market growth. Moreover, there is a growing interest in stem cell transplantation, especially from matched unrelated donors, as an emerging curative treatment option. Additionally, there's a rising emphasis on supportive care measures such as pain management, infection prevention, and the use of hydroxyurea therapy. Furthermore, personalized medicine approaches and patient-centered care models are gaining prominence to optimize treatment outcomes for individuals with sickle cell disease.

In the realm of hemoglobin disorders, blood transfusion is the primary treatment method. The frequency of blood transfusions is higher in thalassemia cases compared to other hemoglobinopathies. Transfusions are typically administered every 3 to 4 weeks to maintain normal blood component levels. However, frequent blood transfusions carry an increased risk of infectious diseases and elevated blood iron levels. In 2020, the blood supply was disrupted due to COVID-19 lockdowns in many countries, but it has since been restored and is anticipated to reach its full potential status during the forecast period. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant region in the global Hemoglobinopathies market in 2023. The growth of the hemoglobinopathies market in the region is driven by increased awareness among the public and the continuous enhancement of healthcare infrastructure. Additionally, initiatives taken by academic research institutions to develop novel therapies for the treatment of hemoglobinopathies in the region especially in the United States is further expected to support the market growth in the region. According to clinicaltrials.gov, there are around 733 clinical trials, in different phases of development in United States related to hemoglobinopathies, highlighting the role of United States as a pioneer of research related to hemoglobinopathies.

The Asia-Pacific market is poised to be the fastest-growing market owing to large patient population being affected by sickle cell disease and thalassemia. The market is further boosted by government initiatives aimed at enhancing the quality of care for individuals with hemoglobinopathies. For example, in May 2023, the Union Minister of State for Health and Family Welfare unveiled the third phase of the Health Ministry's Thalassemia Bal Sewa Yojana. Additionally, the government introduced the Thalassemia Bal Sewa Yojana Portal as part of these efforts.

Key Market Players

Sangamo Therapeutics, Inc.

Pfizer, Inc. (Global Blood Therapeutics, Inc.)

bluebird bio, Inc.

Emmaus Medical, Inc.

Novartis AG

Prolong Pharmaceuticals, LLC

Sanofi S.A. (Bioverativ Inc.)

Gamida Cell Ltd.

Celgene Corporation

Abbott Laboratories, Inc.

Report Scope:

In this report, the Global Hemoglobinopathies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemoglobinopathies Market,By Type:

• Thalassemia
• Sickle Cell Disease
• Other Hemoglobin (Hb) Variants

Hemoglobinopathies Market,By Diagnosis:

• Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}
• Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}
• Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}

Hemoglobinopathies Market,By Therapy:

• Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}
• Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}
• Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others}

Hemoglobinopathies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemoglobinopathies Market.

Available Customizations:

Global Hemoglobinopathies marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.GlobalHemoglobinopathies MarketOutlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)
  • 5.2.2.By Diagnosis (Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}, Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}, Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others})
  • 5.2.3.By Therapy (Thalassemia {BloodTransfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}, Sickle Cell Disease {BloodTransfusion, Hydroxyurea, Bone Marrow Transplant, Others}, Other {BloodTransfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others})
  • 5.2.4.By Region
  • 5.2.5.By Company (2023)
• 5.3.Market Map

6.North America Hemoglobinopathies Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByType
  • 6.2.2.By Diagnosis
  • 6.2.3.By Therapy
  • 6.2.4.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Hemoglobinopathies Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Diagnosis
      • 6.3.1.2.3.By Therapy
  • 6.3.2.Canada Hemoglobinopathies Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Diagnosis
      • 6.3.2.2.3.By Therapy
  • 6.3.3.Mexico Hemoglobinopathies Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Diagnosis
      • 6.3.3.2.3.By Therapy

7.Europe Hemoglobinopathies Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Diagnosis
  • 7.2.3.By Therapy
  • 7.2.4. By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany Hemoglobinopathies Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Diagnosis
      • 7.3.1.2.3.By Therapy
  • 7.3.2.United Kingdom Hemoglobinopathies Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Diagnosis
      • 7.3.2.2.3.By Therapy
  • 7.3.3.Italy Hemoglobinopathies Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Diagnosis
      • 7.3.3.2.3.By Therapy
  • 7.3.4.France Hemoglobinopathies Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Diagnosis
      • 7.3.4.2.3.By Therapy
  • 7.3.5.Spain Hemoglobinopathies Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Diagnosis
      • 7.3.5.2.3.By Therapy

8.Asia-Pacific Hemoglobinopathies Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Diagnosis
  • 8.2.3.By Therapy
  • 8.2.4. By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Hemoglobinopathies Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Diagnosis
      • 8.3.1.2.3.By Therapy
  • 8.3.2.India Hemoglobinopathies Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Diagnosis
      • 8.3.2.2.3.By Therapy
  • 8.3.3.Japan Hemoglobinopathies Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Diagnosis
      • 8.3.3.2.3.By Therapy
  • 8.3.4.South Korea Hemoglobinopathies Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Type
      • 8.3.4.2.2.By Diagnosis
      • 8.3.4.2.3.By Therapy
  • 8.3.5.Australia Hemoglobinopathies Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Type
      • 8.3.5.2.2.By Diagnosis
      • 8.3.5.2.3.By Therapy

9.South America Hemoglobinopathies Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Diagnosis
  • 9.2.3.By Therapy
  • 9.2.4. By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Hemoglobinopathies Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Diagnosis
      • 9.3.1.2.3.By Therapy
  • 9.3.2.Argentina Hemoglobinopathies Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Diagnosis
      • 9.3.2.2.3.By Therapy
  • 9.3.3.Colombia Hemoglobinopathies Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Diagnosis
      • 9.3.3.2.3.By Therapy

10.Middle East and Africa Hemoglobinopathies Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Diagnosis
  • 10.2.3.By Therapy
  • 10.2.4. By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Hemoglobinopathies Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Diagnosis
      • 10.3.1.2.3.By Therapy
  • 10.3.2.Saudi Arabia Hemoglobinopathies Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Diagnosis
      • 10.3.2.2.3.By Therapy
  • 10.3.3.UAE Hemoglobinopathies Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Diagnosis
      • 10.3.3.2.3.By Therapy

11.Market Dynamics

• 11.1.Drivers
• 11.2. Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Product Launches
• 12.3.Mergers Acquisitions

13.Global Hemoglobinopathies Market: SWOT Analysis

14.Competitive Landscape

• 14.1.Sangamo Therapeutics, Inc.
  • 14.1.1.Business Overview
  • 14.1.2.Product Service Offerings
  • 14.1.3.Recent Developments
  • 14.1.4.Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2.Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• 14.3.bluebird bio, Inc.
• 14.4.Emmaus Medical, Inc.
• 14.5.Novartis AG
• 14.6.Prolong Pharmaceuticals, LLC
• 14.7.Sanofi S.A. (Bioverativ Inc.)
• 14.8.Gamida Cell Ltd.
• 14.9.Celgene Corporation
• 14.10. Abbott Laboratories, Inc.

15.Strategic Recommendations

16.About Us Disclaimer